Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

CANF has been the topic of a number of other reports. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

NYSE CANF opened at $1.81 on Thursday. The stock has a 50-day simple moving average of $1.85 and a 200 day simple moving average of $2.35. Can-Fite BioPharma has a twelve month low of $1.29 and a twelve month high of $4.69. The stock has a market capitalization of $6.41 million, a PE ratio of -1.01 and a beta of 1.32.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC lifted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.